Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The type 1 insulin-like growth factor receptor pathway.

Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM.

Clin Cancer Res. 2008 Oct 15;14(20):6364-70. doi: 10.1158/1078-0432.CCR-07-4879. Review.

2.

IGF1R signalling and its inhibition.

Riedemann J, Macaulay VM.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S33-43. Review.

3.

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.

Iams WT, Lovly CM.

Clin Cancer Res. 2015 Oct 1;21(19):4270-7. doi: 10.1158/1078-0432.CCR-14-2518. Review.

4.

Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.

Tao Y, Pinzi V, Bourhis J, Deutsch E.

Nat Clin Pract Oncol. 2007 Oct;4(10):591-602. Review.

PMID:
17898809
5.

Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment.

Bohula EA, Playford MP, Macaulay VM.

Anticancer Drugs. 2003 Oct;14(9):669-82. Review.

PMID:
14551500
6.

InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.

Ma Y, Tang N, Thompson RC, Mobley BC, Clark SW, Sarkaria JN, Wang J.

Clin Cancer Res. 2016 Apr 1;22(7):1767-76. doi: 10.1158/1078-0432.CCR-15-1677. Epub 2015 Nov 11.

7.

Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy.

Tognon CE, Sorensen PH.

Expert Opin Ther Targets. 2012 Jan;16(1):33-48. doi: 10.1517/14728222.2011.638626. Epub 2012 Jan 12. Review.

PMID:
22239439
8.

The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma.

Ewing GP, Goff LW.

Clin Colorectal Cancer. 2010 Oct;9(4):219-23. doi: 10.3816/CCC.2010.n.032. Review.

PMID:
20920993
9.

Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Li R, Pourpak A, Morris SW.

J Med Chem. 2009 Aug 27;52(16):4981-5004. doi: 10.1021/jm9002395. Review. No abstract available.

10.
11.

The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer.

Haisa M.

J Int Med Res. 2013 Apr;41(2):253-64. doi: 10.1177/0300060513476585. Epub 2013 Mar 5. Review.

PMID:
23569026
12.

Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.

Vincent EE, Elder DJ, Curwen J, Kilgour E, Hers I, Tavaré JM.

PLoS One. 2013 Jun 24;8(6):e66963. doi: 10.1371/journal.pone.0066963. Print 2013.

13.

Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.

Zeng X, Zhang H, Oh A, Zhang Y, Yee D.

Breast Cancer Res Treat. 2012 May;133(1):117-26. doi: 10.1007/s10549-011-1713-x. Epub 2011 Aug 18.

14.

Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.

Fagan DH, Uselman RR, Sachdev D, Yee D.

Cancer Res. 2012 Jul 1;72(13):3372-80. doi: 10.1158/0008-5472.CAN-12-0684. Epub 2012 May 9.

15.

Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia.

Yaktapour N, Übelhart R, Schüler J, Aumann K, Dierks C, Burger M, Pfeifer D, Jumaa H, Veelken H, Brummer T, Zirlik K.

Blood. 2013 Aug 29;122(9):1621-33. doi: 10.1182/blood-2013-02-484386. Epub 2013 Jul 17.

16.

Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction.

Sarfstein R, Werner H.

Endocrinology. 2013 May;154(5):1672-9. doi: 10.1210/en.2012-2165. Epub 2013 Mar 18. Review.

PMID:
23507573
17.

Epitope-specific mechanisms of IGF1R inhibition by ganitumab.

Calzone FJ, Cajulis E, Chung YA, Tsai MM, Mitchell P, Lu J, Chen C, Sun J, Radinsky R, Kendall R, Beltran PJ.

PLoS One. 2013;8(2):e55135. doi: 10.1371/journal.pone.0055135. Epub 2013 Feb 1.

18.

Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.

Hu YP, Patil SB, Panasiewicz M, Li W, Hauser J, Humphrey LE, Brattain MG.

Cancer Res. 2008 Oct 1;68(19):8004-13. doi: 10.1158/0008-5472.CAN-08-0280.

20.

Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.

Hendrickson AW, Haluska P.

Curr Opin Investig Drugs. 2009 Oct;10(10):1032-40. Review.

PMID:
19777391

Supplemental Content

Support Center